New Treatment For Overactive Bladder
The U.S. Food
and Drug Administration has approved the new drug Vesicare (solifenacin
succinate) to treat symptoms of overactive bladder, the drug's makers said.
Overactive bladder
(OAB) is a condition that causes the bladder muscle to contract while the
organ is filling, rather than when it is full. People with the condition
feel the urge to urinate more frequently, often without warning. OAB affects
up to 20 million men and women in the United States, reported the drug's
makers, GlaxoSmithKline and Japan's Yamanouchi Pharmaceutical Co.
Approval of
Vesicare followed four 12-week trials involving more than 3,000 people
with OAB symptoms, including the urge to urinate more frequently and the
accidental leakage of urine, the companies said in a prepared statement.
The most common side effects were dry mouth, constipation, and blurred
vision.
--
Copyright 2005 by United
Press International.
All rights reserved.
--
|